PEER
PEER-REVIE
EER-REVIEW DERMA OLOG | | DERMAT ERMATOLOGY
A POLYNUCLEOTIDE–BASED PRODUCT TO TREAT
Torello Lotti, Roberto Gianfaldoni, Serena Gianfaldoni and Andrea Nannipieri discuss the findings of their study on a
HORMONAL HAIR LOSS
FEMALE
treatment for hormone dependent hair loss in women and its implications for the future treatment of this condition
ABSTRACT Androgen-dependent female hair loss is a disease affecting 40–50% of all women1
. Its
onset may occur at any age between puberty and the menopause, and it can be triggered by a number of different mechanisms. Essentially, it is supported by a lack of oestrogen and takes the form of progressive miniaturisation of the single hairs. In this study, the authors proposed to investigate the therapeutic effect of a product based on polydeoxyribonucleotides in women with hormone-dependent hair loss, administered
TORELLO LOTTI MD, CMO, is Chair of Dermatology, University of Rome “G. Marconi”, Rome, Italy; ROBERTO GIANFALDONI, SERENA GIANFALDONI, ANDREA NANNIPIERI, Department of Dermatology, Santa Chiara Hospital, Pisa, Italy;
email:
professor@torellolotti.it
KEYWORDS androgenetic alopecia, polynucleotides, polydeoxyribonucleotide, trichogram, dermatoscopy
16 F EMALE HORMONAL
by means of intradermal infiltrations carried out according to standard timing for a period of 4 months. The results were assessed by means of photographic documentation, pull tests, trichograms, wash tests and dermatoscopy for counting the average number of hairs and the diameters of the hair shafts, at time 0 and after 30, 60 and 120 days. The results achieved were satisfactory for all the patients and no side-effects were observed. The authors found that all patients were generally satisfied, and this feeling increased progressively alongside
HAIR LOSS
(female androgenetic alopecia; FAGA) affects approximately 40–50% of all women1
, often causing significant
psychological repercussions on top of the damage in functional terms and of
appearance. The onset of female hair loss can occur at any age, from puberty right through to old age; indeed, whenever changes in the oestrogen–progesterone balance take place2
.
Possible triggering factors include the start or suspension of contraceptive therapy, pre-partum or
July/August 2014 |
prime-journal.com
COVER STORY
the objective results. The pull tests normalised progressively and the trichograms recorded gradual recovery of the anagen-telogen ratio, with an increase in the number of hairs in the anagen phase. The number of hairs falling out decreased (wash test) and, consequently, the hair became thicker and the structural size of the shafts increased (dermatoscopy). To conclude, the authors believe that the results achieved confirm the trophic stimulus exercised by the polynucleotides on the hair follicles of the scalp for female hair loss.
post-partum modifications, pregnancy, stressful events or dietary deficiencies.
Female hormonal hair loss Thinning of the hair can occur in a number of ways: In the prevailing pattern (female pattern) a reduction in the concentration of the hair is observed in a triangular-shaped frontal area behind a persistent fringe (Christmas tree pattern)
The thinning may affect the vertex area (Ludwig Pattern) in accordance with Types I, II or III, depending on how severe the hair loss is (Table 1)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56